ANG and ovarian carcinoma: Thus, the hypothesis to which our work leads is whether the optimum position of Ang/Tie inhibitors in ovarian cancer is when there is evidence of vascular progression based on a rising plasma Tie2 concentration in patients receiving treatment with a VEGF pathway inhibitor.